The upregulation of phosphorylation of PDGFR in turn activates the two major PDGFR-mediated pathways involved in the increased drug resistance in A549 NSCLC cells: the Akt-mTOR and Raf-MEK pathways. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.